- Trials with a EudraCT protocol (102)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (6)
102 result(s) found for: Mucus.
Displaying page 1 of 6.
EudraCT Number: 2019-004182-41 | Sponsor Protocol Number: 7774 | Start Date*: 2021-11-29 |
Sponsor Name:University hospital of Montpellier | ||
Full Title: Chronic airway disease, mucus rheology and exacerbations: a randomized controlled trial of COPD patients (COPD-CARhE) | ||
Medical condition: COPD (CHRONIC OBSTUCTIVE PULMONARY DISEASE) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2022-003303-14 | Sponsor Protocol Number: DETACT | Start Date*: 2023-02-16 |
Sponsor Name:Medical University of Vienna | ||
Full Title: Effect of Dupilumab on mucus plugs and inflammatory patterns in sEvere asThmatiC paTients (DETACT) | ||
Medical condition: Severe asthma is a chronic inflammatory condition of the airways, characterized with wheezing, breathlessness, chest tightness and coughing. T2-high asthma is promoted by differentiated T helper c... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2007-003739-22 | Sponsor Protocol Number: GAL-01-2007 | Start Date*: 2007-10-04 | |||||||||||
Sponsor Name:GALSOR S.R.L. | |||||||||||||
Full Title: Safety and efficacy (for the symptom remission) of the treatment adjuvant of the antibiotic therapy of the acute episode of sinusitis (acute, subacute, chronic)with Ecballium Elaterium (SINUclean D... | |||||||||||||
Medical condition: Acute sinusitis or exacerbation of subacute or chronic sinusitis. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-004377-44 | Sponsor Protocol Number: Ambroxpall | Start Date*: 2021-08-24 |
Sponsor Name:Med. Univ. Wien, Innere Med. I, Abt. f. Palliativmedizin | ||
Full Title: Ambroxol inhalation for mucus clearance in palliative care patients - a randomized placebo-controlled double-blind pilot study. | ||
Medical condition: cancer | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2008-008900-42 | Sponsor Protocol Number: MUMC29-12-2008 | Start Date*: 2009-06-10 |
Sponsor Name:MUMC | ||
Full Title: The DIEP flap as a model of ischemia-reperfusion: an intervention study | ||
Medical condition: ischemia reperfusion | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Female | |
Trial protocol: NL (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2018-002579-16 | Sponsor Protocol Number: CF001 | Start Date*: 2018-08-26 | |||||||||||
Sponsor Name:Karolinska University Hospital, Stockholm CF center | |||||||||||||
Full Title: Evaluation of the possible use of analysis of posaconazole in exhaled breath as a surrogate marker for the lung to monitor adequate dosages of posaconazole in CF patients treated for Aspergillus sp... | |||||||||||||
Medical condition: Cystic Fibrosis (CF) is the most common life–limiting autosomal recessive disease among people of European heritage. The condition is a result of a mutation in the cystic fibrosis transmembrane con... | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-005452-41 | Sponsor Protocol Number: DPM-B-301 | Start Date*: 2006-05-26 |
Sponsor Name:Pharmaxis UK Limited | ||
Full Title: A phase III Multicenter, randomised, parallel, placebo-controlled, double-blind study to investigate the safety and efficacy of treatment with Bronchitol (dry powder mannitol) in the symptomatic tr... | ||
Medical condition: Bronchiectasis | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2022-000152-11 | Sponsor Protocol Number: D3250R00107 | Start Date*: 2022-10-20 | |||||||||||
Sponsor Name:AstraZeneca AB | |||||||||||||
Full Title: BURAN: Effects of Benralizumab on Airway Dynamics in Severe Eosinophilic Asthma using Functional Respiratory Imaging Parameters | |||||||||||||
Medical condition: Asthma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) ES (Completed) PT (Completed) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-001097-24 | Sponsor Protocol Number: PHT/2013/01 | Start Date*: 2013-05-23 | |||||||||||
Sponsor Name:Portsmouth Hospitals NHS trust | |||||||||||||
Full Title: Use of N-Acetylcysteine (NAC) and Simeticone as a pre-endoscopic drink to improve mucosal visualisation during gastroscopy: A randomised controlled trial | |||||||||||||
Medical condition: Early gastrointestinal lesions in the upper gastrointestinal tract. Our study is not looking at the direct treatment of any particular condition, but the early detecton of lesions. When performin... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-001026-62 | Sponsor Protocol Number: ETGOL | Start Date*: 2021-10-05 | |||||||||||
Sponsor Name:University Hospital Dr Josep Trueta | |||||||||||||
Full Title: Benefits of inhalation of 7% hypertonic saline solution prior to ELTGOL physiotherapy, in patients with bronchiectasis. A randomized controlled trial. | |||||||||||||
Medical condition: bronchiectasis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-006276-11 | Sponsor Protocol Number: VR496/005 | Start Date*: 2008-09-01 | |||||||||||
Sponsor Name:Vectura Limited | |||||||||||||
Full Title: A Phase I/II randomised, placebo-controlled, double blind trial to assess the safety, tolerability, pharmacodynamics and exploratory efficacy of heparin 25 mg inhalation powder in patients with Cys... | |||||||||||||
Medical condition: Cystic Fibrosis | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) IE (Completed) PL (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-003774-27 | Sponsor Protocol Number: BC-180-12 | Start Date*: 2014-01-20 |
Sponsor Name:AlgiPharma AS | ||
Full Title: An open label, randomised, two-way crossover scintigraphic study to investigate lung deposition of radiolabelled OligoG delivered as a dry powder and as a nebulised solution in cystic fibrosis pati... | ||
Medical condition: Cystic fibrosis (CF) is an autosomal, recessive inheritable disease caused by a homozygote defect at the long arm of Chromosome 7. This mutation causes absence or defect of the cystic fibrosis tran... | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2005-004344-30 | Sponsor Protocol Number: Moli1901-010A | Start Date*: 2005-10-31 |
Sponsor Name:AOP Orphan Pharmaceuticals AG | ||
Full Title: An Evaluation of the Safety and Tolerability of Multiple Dose Regimens of Aerosolized Moli1901 in Adolescents (12 Years of Age or Older) and Adults with Cystic Fibrosis and Stable Lung Disease | ||
Medical condition: Cystic fibrosis is the most common fatal inherited disease in the Caucasian population, affecting about 4 in 10,000 children. In cystic fibrosis chloride transport across the respiratory epithelium... | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: AT (Completed) HU (Completed) | ||
Trial results: View results |
EudraCT Number: 2019-004647-74 | Sponsor Protocol Number: LPS15834 | Start Date*: 2020-10-27 | |||||||||||
Sponsor Name:Sanofi-Aventis Groupe | |||||||||||||
Full Title: Randomized, double blind, placebo controlled study to evaluate the effect of dupilumab on airway inflammation through assessments of lung function, mucus plugging and other lung imaging parameters ... | |||||||||||||
Medical condition: Asthma | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) DK (Completed) SE (Ongoing) PT (Completed) ES (Ongoing) BG (Completed) FR (Completed) IT (Completed) RO (Ongoing) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-001714-24 | Sponsor Protocol Number: BTA798-CL2-001 | Start Date*: 2008-06-18 |
Sponsor Name:Biota Scientific Management Pty Ltd | ||
Full Title: A Phase II, Double-Blind Placebo-Controlled Study to Determine the Prophylactic Efficacy of Oral BTA798 in an Experimental Rhinovirus Challenge Model | ||
Medical condition: BTA798 is an investigational drug being developed as a potential agent for treatment and prevention of the common cold. | ||
Disease: | ||
Population Age: Adults | Gender: Male | |
Trial protocol: GB (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2014-003581-25 | Sponsor Protocol Number: APA-III | Start Date*: 2015-05-26 |
Sponsor Name:University Hospital Tuebingen | ||
Full Title: Anti-inflammatory pulmonal therapy of CF-patients with Amitriptyline and Placebo - Randomised, double-blind, placebo-controlled cohort trial | ||
Medical condition: Amitriptyline reduces ceramide concentrations in bronchial epithelial cells and reduces cell death and reduces the deposition of DNA on the respiratory epithelium. This reduction promotes the elimi... | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: DE (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2006-004162-13 | Sponsor Protocol Number: SAE-13/IBD | Start Date*: 2007-02-27 | |||||||||||
Sponsor Name:Charité Universitätsmedizin, Campus Charité Mitte | |||||||||||||
Full Title: Randomized, double-blind, placebo-controlled phase II pilot study of the impact of mesalazine enemas on the mucosal gut flora in patients with inflammatory bowel disease | |||||||||||||
Medical condition: Active inflammatory bowel disease, i.e. either left-sided ulcerative colitis or Crohn´s Disease (Colon) with signs of inflammation within 40 cm ab ano. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-003249-15 | Sponsor Protocol Number: E-BRO-3 | Start Date*: 2005-09-26 |
Sponsor Name:BIONORICA AG | ||
Full Title: Efficacy and tolerability of Bronchipret® Saft for the treatment of acute bronchitis in adults A randomized, double-blind, placebo-controlled, parallel-group, multicenter Phase IV study. | ||
Medical condition: Acute bronchitis with productive cough i.e. onset of bronchial mucus production with impaired ability to cough up. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2022-003219-26 | Sponsor Protocol Number: MR-130A-01-TD-2001 | Start Date*: 2023-01-10 | |||||||||||
Sponsor Name:Mylan Pharmaceuticals, Inc | |||||||||||||
Full Title: An open-label, phase II, dose-finding study of three dose strengths of MR-130A-01 contraceptive transdermal patch containing norelgestromin (NGMN) in healthy pre-menopausal women | |||||||||||||
Medical condition: Investigation of ovulation inhibition for indication of contraception in healthy subjects | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-002098-30 | Sponsor Protocol Number: | Start Date*: 2006-09-04 |
Sponsor Name:Erasmus Medical Centre Rotterdam | ||
Full Title: Efficacy of Inhaled RhDNase in Mechanically Ventilated Pediatric Patients with an Atelectasis | ||
Medical condition: Study population are: Children who develop an atelectasis during mechanical ventilation. An atelectasis is a collapsed part of the lung that is often caused by mucus plugs. | ||
Disease: | ||
Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
